Additional clinical data from RESET trials expected throughout 2026 (GlobeNewswire) - Nov 10, 2025 - "On December 6, 2025, Cabaletta will present a poster...In addition, Cabaletta plans to present complete Phase 1/2 data from the RESET-SSc and RESET-SLE trials in the first half of 2026 and from the RESET-MG trial in the second half of 2026. The Company also anticipates clinical data on rese-cel without preconditioning from the initial RESET-SLE dose-escalation cohort and additional dosing from the RESET-PV trial in 2026."
P1/2 data • Myasthenia Gravis • Pemphigus Vulgaris • Systemic Lupus Erythematosus • Systemic Sclerosis
|